TEE
NYMX

Tibra Equities Europe’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Tibra Equities Europe’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-151,100
Closed -$239K – 225
2021
Q2 		$239K Buy
+151,100
New +$280K 0.07% 221

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tibra Equities Europe's NYMX Position: Q3 2021 in Review

Tibra Equities Europe sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2021, closing a stake of 151,100 shares — an estimated $239K sold.

Tibra Equities Europe first reported a position in NYMX in Q2 2021 and held it in 1 quarter. The position peaked at $239K in Q2 2021. 38 funds tracked by Wall St. Rank hold NYMX as of Q3 2021.

  • Tibra Equities Europe reported no remaining Nymox Pharmaceutical Corp position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 151,100 Nymox Pharmaceutical Corp shares in Q3 2021, an estimated $239K.
  • Tibra Equities Europe first reported a position in Nymox Pharmaceutical Corp in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's Nymox Pharmaceutical Corp position peaked at $239K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.